The FDA has approved Roche (OTCQX:RHHBY) unit Genentech’s Tecentriq (atezolizumab), combined with chemo agents carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer

More than 1,200 children were diagnosed with some form of cancer over a 10 year period in Scotland, statistics have revealed. From 2007 to 2016, 1,275 people aged 14 or

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to

Affimer technology offers unique solutions in the field of affinity purification through the ability to develop highly specific and stable capture reagents for a wide-range of novel targets. The robust

Dr Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Dr Williams is joining Avacta and very much look forward to working with him. Sam has extensive experience

Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted that Dr Jose Saro is joining Avacta to lead the therapeutic development strategy and to drive the in-house Affimer®